Fludarabine + Treosulfan
Phase 2Small molecule
Fludarabine + Treosulfan is one of 32 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
804 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Phase 3
Dalalone
CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 3
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Lenograstim
SanofiPhase 3
Caspofungin Acetate
Merck & Co.Phase 3
Experimental
BiogenPhase 3
AG-120
Institut de Recherches Internationales ServierPhase 3
Valspodar
EEastern Cooperative Oncology Group
Phase 3
Salvage Chemotherapy
Daiichi SankyoPhase 3
Homoharringtonine
Ascentage Pharma Group Inc.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia1 trial
Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia
Active, not recruiting·AAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia·Phase 2·NCT07232953·82 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fludarabine + Treosulfan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details